Elitra Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Elitra Pharmaceuticals Inc. has developed a rapid and systematic method to sequence the entire genome of microbial organisms. It will identify the genes essential to the organisms' survival and use its proprietary bioinformatics platform to prioritize and validate gene targets. Alone and with partners, it will develop and commercialize novel antibiotic and antifungal drugs to inhibit the growth of major microbial pathogens, many of which are becoming resistant to current therapeutics.
You may also be interested in...
Where Are They Now?
In a new occasional series, START-UP will select companies it profiled in the past to find out what went according to plan, and what didn't. This month, we revisit four anti-infectives discovery companies first profiled in 2000 and draw out some lessons, both from their successes and from their failures, for those starting out today.
Where Are They Now?
In a new occasional series, START-UP will select companies it profiled in the past to find out what went according to plan, and what didn't. This month, we revisit four anti-infectives discovery companies first profiled in 2000 and draw out some lessons, both from their successes and from their failures, for those starting out today.
Novel Anti-Infectives
The introduction of new anti-infective drugs has not kept pace with the ability of bacteria to resist and render ineffective just about all antibiotics developed since the late 1920's. Influenza, hepatitis, pneumonia, meningitis, AIDS, tuberculosis and plenty of other infections are killing people, and not just in third world countries. In the US, infection is the third leading cause of death, behind heart disease and cancer. Since the mid-90's, the seriousness of the bacterial drug resistance problem has caused pharmaceutical companies to redouble their R&D efforts. And the problem has spawned a new industry of start-ups as well. Elitra Pharmaceuticals and Arrow Therapeutics hope to add to the anti-infective armamentarium with drugs that attack targets necessary for bacterial growth and survival. EluSys Therapeutics has an immunological approach, taking advantage of bispecific antibodies to clear toxins and pathogens from the bloodstream. Paratek Pharmaceuticals has taken a different approach. It's attacking the mechanism of resistance directly.